Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Fingolimod

Fingolimod Reactions 1704, p163 - 2 Jun 2018 Severe aseptic temporal lobe encephalitis: case report A 49-year-old woman developed severe aseptic temporal lobe encephalitis during treatment with fingolimod for relapsing-remitting multiple sclerosis (RRMS). The woman, who had been on fingolimod for 3.5 years [route and dosage not stated] for a 25-year history of RRMS, presented with global aphasia, confusion and holocephalic headache. Additionally, she had been receiving treatment with an angiotensin-II receptor blocker and a proton pump inhibitor [specific drugs not stated]. She had a decline in consciousness within 12 hours of admission, indicated by a Glasgow coma score of 10, and low-grade fever. Her lymphocyte count was low. Baseline Expanded Disability Status Scale was 2 on account of mild cognitive deficits. MRI showed oedema in her bilateral temporal and inferior frontal lobes with patchy gadolinium enhancement, as well as extensive, poorly-defined increased T2 signal. Her protein levels were elevated on day 1. Cryptococcal antibody, bacterial culture and viral PCR were negative. Her blood tests were negative for lyme, HIV and VDRL. A differential diagnosis of aseptic encephalitis was made. Fingolimod was discontinued, and the woman was commenced on systemic antibiotics including ampicillin, vancomycin and ceftriaxone, in combination with acyclovir. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Fingolimod

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018

Fingolimod

Abstract

Reactions 1704, p163 - 2 Jun 2018 Severe aseptic temporal lobe encephalitis: case report A 49-year-old woman developed severe aseptic temporal lobe encephalitis during treatment with fingolimod for relapsing-remitting multiple sclerosis (RRMS). The woman, who had been on fingolimod for 3.5 years [route and dosage not stated] for a 25-year history of RRMS, presented with global aphasia, confusion and holocephalic headache. Additionally, she had been receiving treatment with an angiotensin-II...
Loading next page...
1
 
/lp/springer_journal/fingolimod-0U4CezDzEe

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46806-8
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p163 - 2 Jun 2018 Severe aseptic temporal lobe encephalitis: case report A 49-year-old woman developed severe aseptic temporal lobe encephalitis during treatment with fingolimod for relapsing-remitting multiple sclerosis (RRMS). The woman, who had been on fingolimod for 3.5 years [route and dosage not stated] for a 25-year history of RRMS, presented with global aphasia, confusion and holocephalic headache. Additionally, she had been receiving treatment with an angiotensin-II receptor blocker and a proton pump inhibitor [specific drugs not stated]. She had a decline in consciousness within 12 hours of admission, indicated by a Glasgow coma score of 10, and low-grade fever. Her lymphocyte count was low. Baseline Expanded Disability Status Scale was 2 on account of mild cognitive deficits. MRI showed oedema in her bilateral temporal and inferior frontal lobes with patchy gadolinium enhancement, as well as extensive, poorly-defined increased T2 signal. Her protein levels were elevated on day 1. Cryptococcal antibody, bacterial culture and viral PCR were negative. Her blood tests were negative for lyme, HIV and VDRL. A differential diagnosis of aseptic encephalitis was made. Fingolimod was discontinued, and the woman was commenced on systemic antibiotics including ampicillin, vancomycin and ceftriaxone, in combination with acyclovir.

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.